Home/Blogs/Blog details

Various Types of Cardiomyopathy Devices

Apr 03, 2017

Various Types of Cardiomyopathy Devices

Cardiomyopathy is a group non ischemic heart disease which affects the heart muscles. The disease includes dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy and arrhythmogenic right ventricular dysplasia. As a treatment to heart failure which results from cardiomyopathy various kinds of devices are available in medical science. Let’s have a look at them:

  • Heart Failure Monitor- it is a wireless device which is implanted in the pulmonary artery, which carries blood from heart to lungs. The device measures the pressure in the pulmonary artery which allows the doctor to keep record of the heart functioning and response to medications. The process is done through a minimally invasive procedure, in which a hole is made in the leg and a catheter is inserted through the femoral vein to the pulmonary artery in which a sensor is implanted. The device transmits data to the computer which is interpreted by doctor.
  • Cardioverter Defibrillator- these devices are implanted in the heart muscle which helps detect a dangerous ventricular fibrillation and deliver a series of electrical shock or electrical pulses to restore the normal heart rhythm. Hence the device is called defibrillator.
  • Biventricular Pacemaker- it is a small battery-operated machine which is used to manage arrhythmias, or irregular heartbeats. It is implanted in the chest under the skin, below the right or left clavicle, so that heart can beat at a normal rate. It sends regular electrical signals to heart to help it maintain a regular rhythm and improve the efficiency of the contractions of the heart.

Latest Development: HeartMate 3

The latest winner of the 2016 Cardiostim-EHRA Europace Innovation Award, the Thoratec HeartMate 3 LVAS is capable of pumping 10 liters of blood per minute. According to analysts, more than a million heart failure patients in US are awaiting this implant. The device was approved with CE mark in 2015 after managing a 92% 6-month survival rate during a 2-year of clinical trial.

Disclaimer: The information given in this write-up is purely for educating the reader. It is not meant to be a substitute for any advice from a medical expert.

footer pattern

All Copyrights reserve worldhealthcarenews.biz 2017.